Asked by: Lord Grade of Yarmouth (Non-affiliated - Life peer)
Question to the Department of Health and Social Care:
To ask Her Majesty's Government what lessons they have learnt from the government of Israel’s campaign in response to COVID-19 vaccine hesitancy in that country; and what steps they are taking to apply any such lessons to the deployment of COVID-19 vaccines in the UK.
Answered by Lord Bethell
The Department is regularly in discussions with other countries on a wide range of COVID-19 issues, including Israel, to share learnings and collaborate internationally on the vaccination programme. Feedback from these discussions, where relevant, is used to improve the deployment of COVID-19 vaccines in the United Kingdom.
Asked by: Lord Grade of Yarmouth (Non-affiliated - Life peer)
Question to the Department of Health and Social Care:
To ask Her Majesty's Government what assessment they have made of the case for a single holistic infections strategy that addresses antimicrobial resistance, sepsis, future infections threats, and pandemic preparedness.
Answered by Lord Bethell
The Government has assessed the case for a single holistic infections strategy and agrees with the need to closely align work on antimicrobial resistance, sepsis, future infections threats and pandemic preparedness. This has culminated in the publication of Public Health England’s PHE Infectious Diseases Strategy 2020-2025: Addressing urgent threats in the 21st century outlining priorities to reduce the risk of and burden from all infectious diseases including resistant infections, infections that can lead to sepsis, endemic infections, vaccine-preventable infections, and infections of pandemic potential, and bringing them together as a single strategic framework. A copy of the Strategy is attached.
While the Infectious Diseases Strategy does not address sepsis strategy directly, it is critical that our work on sepsis and anti-microbial resistance (AMR) is closely aligned. Sepsis forms an important part of NHS England and NHS Improvement’s AMR programme, which will continue to drive improvement in the prevention and management of infection and optimal antibiotic use.